Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
November 15 2022 - 4:00PM
Business Wire
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”)
announced today that on November 14, 2022 it priced an offering of
$1.2 billion aggregate principal amount (the “Offering”) of the
following notes:
- $600 million aggregate principal amount of its 4.800% senior
notes due 2027 (the “2027 notes”), at the issue price of 99.960% of
their principal amount, and
- $600 million aggregate principal amount of its 4.950% senior
notes due 2032 (the “2032 notes” and together with the 2027 notes,
the “notes”), at the issue price of 99.797% of their principal
amount.
The Offering is expected to close on or about November 21, 2022,
subject to customary closing conditions. The notes will pay
interest on a semi-annual basis.
Thermo Fisher intends to use the net proceeds from the sale of
the notes for general corporate purposes, which may include the
acquisition of companies or businesses, repayment and refinancing
of debt, working capital and capital expenditures or the repurchase
of its outstanding equity securities or it may temporarily invest
the net proceeds in short-term, liquid investments until they are
used for their ultimate purpose.
The joint book-running managers for the Offering are BofA
Securities, Inc., Citigroup Global Markets Inc. and Deutsche Bank
Securities Inc.
The Offering is being made pursuant to an effective registration
statement on Form S-3 filed with the U.S. Securities and Exchange
Commission (the “SEC”). Prospective investors should read the
prospectus forming a part of that registration statement and the
prospectus supplement related to the Offering and the other
documents that Thermo Fisher has filed with the SEC for more
complete information about Thermo Fisher and the Offering. These
documents are available at no charge by visiting EDGAR on the SEC
website at www.sec.gov. Alternatively, Thermo Fisher, the
underwriters or any dealer participating in the Offering will
arrange to send you the prospectus if you request it by calling
BofA Securities, Inc. toll-free at 1-800-294-1322; Citigroup Global
Markets Inc. toll-free at 1-800-831-9146; or Deutsche Bank
Securities Inc. toll-free at 1-800-503-4611.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about Thermo
Fisher’s intended use of proceeds. These statements involve a
number of risks and uncertainties that could cause actual results
to differ materially from currently anticipated results, including
risks and uncertainties relating to capital markets conditions and
completion of the Offering. Additional important factors and
information regarding Thermo Fisher’s business that could cause
actual results to differ materially from those indicated by such
forward-looking statements are set forth in the prospectus dated
February 25, 2022 and preliminary prospectus supplement dated
November 14, 2022 related to the Offering, which is on file with
the SEC and available in the “Investors” section of our website
under the heading “SEC Filings,” and the documents incorporated by
reference into the prospectus and prospectus supplement. While we
may elect to update forward-looking statements at some point in the
future, we specifically disclaim any obligation to do so, even if
circumstances change and, therefore, you should not rely on these
forward-looking statements as representing our views as of any date
subsequent to today.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue of approximately $40 billion. Our
Mission is to enable our customers to make the world healthier,
cleaner and safer. Whether our customers are accelerating life
sciences research, solving complex analytical challenges,
increasing productivity in their laboratories, improving patient
health through diagnostics or the development and manufacture of
life-changing therapies, we are here to support them. Our global
team delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services,
Patheon and PPD. For more information, please visit
www.thermofisher.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221115006316/en/
Media Contact Information: Sandy Pound Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information: Rafael Tejada Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Sep 2023 to Sep 2024